Business Acquisition and Product Development - Safety Shot Inc. completed the asset purchase of the Sure Shot Dietary Supplement in August 2023, gaining ownership of various assets including intellectual property and trademarks [124]. - The Sure Shot Dietary Supplement is formulated to reduce blood alcohol content and contains 28 active ingredients classified as Generally Regarded As Safe (GRAS) [125]. - The product was launched in December 2023 through the company's website, Amazon, and several Big Box stores, with plans for new flavors and formats [128]. - The Company owns five patents related to the Sure Shot Dietary Supplement, with the most recent patent expiring on November 5, 2035 [149]. - All ingredients in the Sure Shot Dietary Supplement are deemed Generally Recognized as Safe (GRAS) and comply with FDA standards [155]. - The Company is committed to continuous innovation and has built a substantial portfolio of intellectual property to address unmet market needs [135]. Financial Performance - The Company reported a net loss of 15,674,671 for the same period in 2024 [165]. - The Company generated 170,732 in the same period of 2024 [187]. - Cost of sales for the three months ended March 31, 2025 was 2,383,285 for the same period in 2024 [186]. - Total operating expenses decreased to 12,956,552 for the same period in 2024, reflecting a reduction of approximately 58% [188]. - The Company incurred research and development expenses of 141,493 in the same period of 2024 [176]. - Stock-based compensation for the three months ended March 31, 2025 was 8,090,534 in the same period of 2024 [189]. - The Company reported other income of 505,566 in the same period of 2024 [186]. - Net loss for the three months ended March 31, 2025 was 15,674,671 for the same period in 2024 [193]. Research and Development - Research and development expenses increased from 1,637,117 in 2023, reflecting ongoing efforts to enhance existing products and develop new therapeutic options [132]. - Clinical trials conducted from January 29, 2024, to June 10, 2024, showed a statistically significant reduction in Blood Alcohol Content (BAC) with a p-value of 0.002 [131]. Regulatory and Compliance - The Company is subject to various U.S. federal, state, and local regulations affecting the production and sale of its dietary supplement products [150]. - The Company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements [160]. Investment and Financing - A settlement agreement with Bigger Capital was reached on January 20, 2025, involving a payment of 5.25 million [136]. - The Secured Convertible Bigger Note has a 9% annual interest rate and can be converted into shares of common stock at a conversion price of 14,580,395.73 [147]. Operational Strategy - The company primarily sells products through e-commerce platforms, focusing on customer experience and brand promotion to drive growth [133]. - Manufacturing is outsourced to contract manufacturers in India and the US, with products shipped to third-party warehouses for distribution [134]. - The Company redirected its focus on the acquisition of Yerbae Brands Inc. and plans to implement a new marketing strategy in the second quarter of 2025 [187]. Shareholder Information - The weighted-average number of common shares outstanding increased to 69,258,402 in Q1 2025 from 47,435,503 in Q1 2024 [165]. - Basic and diluted loss per share for Q1 2025 was 0.33 for Q1 2024 [166]. - The Company has not recorded any cash equivalents as of March 31, 2025, or December 31, 2024 [163]. - The Company utilizes the equity method for investments in unconsolidated affiliates, reporting profits and losses in its financial statements [157]. - Deferred tax assets as of March 31, 2025 were approximately $15,362,309, fully offset by a valuation allowance due to the lack of earnings history [175].
Safety Shot(SHOT) - 2025 Q1 - Quarterly Report